Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 8 |
| Clinical Trials and Average Enrollment by Country | 7 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
| Clinical Trials by G7 Countries: Proportion of Schizophrenia to Central Nervous System Clinical Trials | 14 | 1 |
| Clinical Trials by Phase in G7 Countries | 15 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
| Clinical Trials by E7 Countries: Proportion of Schizophrenia to Central Nervous System Clinical Trials | 17 | 1 |
| Clinical Trials by Phase in E7 Countries | 18 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by Phase | 20 | 2 |
| In Progress Trials by Phase | 21 | 1 |
| Clinical Trials by Trial Status | 22 | 1 |
| Clinical Trials by End Point Status | 23 | 1 |
| Subjects Recruited Over a Period of Time | 24 | 1 |
| Clinical Trials by Sponsor Type | 25 | 1 |
| Prominent Sponsors | 26 | 3 |
| Top Companies Participating in Schizophrenia Therapeutics Clinical Trials | 27 | 2 |
| Prominent Drugs | 29 | 1 |
| Latest Clinical Trials News on Schizophrenia | 30 | 7 |
| Oct 03, 2016: Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia | 30 | 1 |
| Sep 28, 2016: Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study 302) | 30 | 2 |
| Sep 26, 2016: Minerva Neurosciences Provides Update on MIN-101 Clinical Program | 32 | 1 |
| Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress | 32 | 1 |
| Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate | 33 | 1 |
| Aug 08, 2016: Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda (lurasidone HCl) in the Treatment of Schizophrenia | 34 | 1 |
| Aug 05, 2016: Allergan and Richter Provide Update on Cariprazine Program | 34 | 1 |
| Aug 01, 2016: Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia | 35 | 2 |
| Clinical Trial Profile Snapshots | 37 | 1277 |
| Appendix | 1314 | 4 |
| Abbreviations | 1314 | 1 |
| Definitions | 1314 | 1 |
| Research Methodology | 1315 | 1 |
| Secondary Research | 1315 | 1 |
| About GlobalData | 1316 | 1 |
| Contact Us | 1316 | 1 |
| Disclaimer | 1316 | 1 |
| Source | 1317 | 1 |
